Fundraising Fox
A28 Therapeutics
La Jolla, US · Founded 2021 · Delaware corporation
Find your way into A28 Therapeutics
Sign up to see every warm intro you have to A28 Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the A28 Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
A28 Therapeutics develops a targeted oncolytic peptide platform for treating multiple cancer types, with its lead candidate AT-101 in late-stage development for metastatic ovarian cancer with liver metastases and hepatocellular carcinoma. The company is also exploring combinations of AT-101 with immuno-oncology drugs and chemotherapy.
Founders & leadership
A28 Therapeutics was founded in 2021 by Stanley Lewis.
SL
Stanley LewisFounder and CEOStanley Lewis is a physician and founder and CEO of A28 Therapeutics, a clinical-stage biotechnology company developing targeted oncolytic peptides for cancer treatment. He previously served as Chief Medical Officer of Ansun Biopharma, where he led late-stage clinical trials for parainfluenza, influenza, and COVID-19 therapies, and as Chief Medical Officer of TaiMed Biologics, where he oversaw development and FDA approval of TROGARZO for multi-drug resistant HIV. He holds an MD from the University of Texas McGovern Medical School and an MPH from the University of Texas School of Public Health.
Board
RB
ROSS BARRETTBoard director
Reported raises · per SEC filings
Form D private placements$1.9M disclosed across 1 round · 2022
▶$1.9MraisedJan 2025 · 26 investors · Other TechnologyRule 506(b)
▶$1.9MraisedJan 2025 · 26 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- STANLEY LEWISExecutive Officer, Director
- ROSS BARRETTDirector
- Offering amount
- $1.9M
- Amount sold
- $1.9M
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
A2 BiotherapeuticsA2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications. The company targets cancer and other serious diseases, advancing its cell therapies through clinical trials.
AN2 TherapeuticsAN2 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs from its boron chemistry platform, with a pipeline spanning hematologic diseases, infectious diseases, oncology, and bone disorders. It targets diseases with significant unmet medical needs.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
Companies working in the same space as A28 Therapeutics.
Frequently asked questions
- What does A28 Therapeutics do?
- A28 Therapeutics develops a targeted oncolytic peptide platform for treating multiple cancer types, with its lead candidate AT-101 in late-stage development for metastatic ovarian cancer with liver metastases and hepatocellular carcinoma. The company is also exploring combinations of AT-101 with immuno-oncology drugs and chemotherapy.
- Who founded A28 Therapeutics?
- A28 Therapeutics was founded by Stanley Lewis in 2021.
- How much funding has A28 Therapeutics raised?
- A28 Therapeutics has disclosed $1.9M raised across 1 round.
- Where is A28 Therapeutics headquartered?
- A28 Therapeutics is headquartered in La Jolla, US.